Figure S1. Screening effective dosage for the retinal NV model induced by

VEGF165+bFGF
Intravitreal injection of 20 μg/mL and 40 μg/mL ART instead of 10 μg/mL ART can notably inhibit vascular dilatation and tortuosity (white arrows) and NV (black arrows) at the margin of medullary wings 1 week after treatment. A: The eye structure and tissue in rabbits treated with ART appeared normal without obvious pathologic change during the follow-up period.
B: No significant differences were found between the three groups and the contralateral eyes. Black corneal endothelial punctate defects (red arrows) were only found in the model group.
C-D:
The cell density (CD）and percentage of hexagonal cells (HEXA) of monkeys were measured at the end of the follow-up period, and no significant differences were found between the three groups and the contralateral eyes.
E-G:
The amplitude of the f-ERG a, b waves of the model group decreased significantly when compared with contralateral eyes and were much improved in the ART and Avastin groups. (* and ** denote p<0.05 and p<0.01 compared to the control group; # and ## denote p<0.05 and p<0.01 compared to the model group; $ and $$ denote p<0.05 and p<0.01 compared to the Avastin group.) H-L: No significant differences were found in the diameter and oxygen saturation of retinal vessels in eyes treated by ART (H-I) or Avastin (J-K) after 6 months compared with levels before intravitreous VEGF165+bFGF.
Significant differences were determined using a t-test or an ANOVA with SPSS 20.0 software, differences with a value of p<0.05 were considered significant. 
